Sharin E. Roth

411 total citations
14 papers, 314 citations indexed

About

Sharin E. Roth is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Sharin E. Roth has authored 14 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 4 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Sharin E. Roth's work include Genetic and Kidney Cyst Diseases (7 papers), Amino Acid Enzymes and Metabolism (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Sharin E. Roth is often cited by papers focused on Genetic and Kidney Cyst Diseases (7 papers), Amino Acid Enzymes and Metabolism (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Sharin E. Roth collaborates with scholars based in United States, United Kingdom and Japan. Sharin E. Roth's co-authors include William J. Brock, Merrie Mosedale, Paul B. Watkins, Kim L. R. Brouwer, J. Scott Eaddy, Rachel J. Church, James J. Beaudoin, Lisl K.M. Shoda, Vicente E. Torres and Linsey Stiles and has published in prestigious journals such as Journal of the American Society of Nephrology, Journal of Pharmaceutical Sciences and American Journal of Kidney Diseases.

In The Last Decade

Sharin E. Roth

14 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sharin E. Roth United States	12	105	91	88	48	47	14	314
Longli Kang China	12	105 1.0×	43 0.5×	141 1.6×	91 1.9×	32 0.7×	36	347
Weize Huang United States	13	89 0.8×	23 0.3×	125 1.4×	106 2.2×	10 0.2×	29	341
Justine L. Lam United States	11	165 1.6×	28 0.3×	182 2.1×	243 5.1×	36 0.8×	16	454
Matthew M. Riggs United States	11	45 0.4×	37 0.4×	179 2.0×	100 2.1×	27 0.6×	24	524
Svetlana Markova United States	11	33 0.3×	23 0.3×	113 1.3×	96 2.0×	36 0.8×	19	415
Carin A.T.C. Lunenburg Netherlands	9	109 1.0×	30 0.3×	130 1.5×	226 4.7×	32 0.7×	12	358
Patricia Macanas-Pirard United Kingdom	9	148 1.4×	25 0.3×	114 1.3×	87 1.8×	22 0.5×	13	387
Cristina Lucía Dávila-Fajardo Spain	13	77 0.7×	41 0.5×	94 1.1×	53 1.1×	24 0.5×	24	367
P. C. Giulianotti Italy	11	22 0.2×	48 0.5×	81 0.9×	73 1.5×	16 0.3×	28	330

Countries citing papers authored by Sharin E. Roth

Since Specialization

Citations

This map shows the geographic impact of Sharin E. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharin E. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharin E. Roth more than expected).

Fields of papers citing papers by Sharin E. Roth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharin E. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharin E. Roth. The network helps show where Sharin E. Roth may publish in the future.

Co-authorship network of co-authors of Sharin E. Roth

This figure shows the co-authorship network connecting the top 25 collaborators of Sharin E. Roth. A scholar is included among the top collaborators of Sharin E. Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharin E. Roth. Sharin E. Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Alpers, David, James H. Lewis, Christine M. Hunt, et al.. (2022). Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. American Journal of Kidney Diseases. 81(3). 281–293.e1. 22 indexed citations

Gibson, Andrew, et al.. (2020). Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury. Chemical Research in Toxicology. 33(11). 2745–2748. 14 indexed citations

Gibson, Andrew, et al.. (2020). Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicological Sciences. 179(1). 95–107. 8 indexed citations

Hayek, Salim S., Douglas Landsittel, Changli Wei, et al.. (2019). Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology. 30(7). 1305–1313. 23 indexed citations

Bezençon, Jacqueline, James J. Beaudoin, Katsuaki Ito, et al.. (2019). Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease. Drug Metabolism and Disposition. 47(8). 899–906. 16 indexed citations

Roth, Sharin E., Mark Avigan, David L. Bourdet, et al.. (2019). Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development. Clinical Pharmacology & Therapeutics. 107(2). 333–346. 30 indexed citations

Brock, William J., James J. Beaudoin, Mingming Su, et al.. (2018). Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. International Journal of Toxicology. 37(2). 144–154. 16 indexed citations

Beaudoin, James J., Jacqueline Bezençon, Yanguang Cao, et al.. (2018). Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug Metabolism and Disposition. 47(2). 155–163. 12 indexed citations

Mosedale, Merrie, J. Scott Eaddy, O. Joseph Trask, et al.. (2017). miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model. Toxicological Sciences. 161(1). 149–158. 40 indexed citations

10.

Woodhead, Jeffrey L., William J. Brock, Sharin E. Roth, et al.. (2016). Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicological Sciences. 155(1). 61–74. 71 indexed citations

11.

Mosedale, Merrie, Yunjung Kim, William J. Brock, et al.. (2016). Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach. Toxicological Sciences. 156(2). kfw269–kfw269. 38 indexed citations

12.

Gall, Émilie Cornec-Le, Olivier Devuyst, Ron T. Gansevoort, et al.. (2016). SP262CAN WE FURTHER ENRICH ADPKD CLINICAL TRIALS FOR RAPIDLY PROGRESSIVE PATIENTS? APPLICATION OF THE PROPKD SCORE IN THE TEMPO TRIAL. Nephrology Dialysis Transplantation. 31(suppl_1). i174–i174. 1 indexed citations

13.

Meng, Min, et al.. (2015). Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC–MS/MS. Journal of Chromatography B. 1002. 78–91. 12 indexed citations

14.

Costantino, Henry R., Lishan Chen, Daniel L. Morris, et al.. (2009). Development of Calcitonin Salmon Nasal Spray: Similarity of Peptide Formulated in Chlorobutanol Compared to Benzalkonium Chloride as Preservative. Journal of Pharmaceutical Sciences. 98(10). 3691–3706. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact